GEO series

Improved antitumor activity of immunotherapy combined with BRAF and MEK inhibitors in BRAFV600E mutant melanoma

GSE64102 Mus musculus (mouse) Expression microarray 13 samples Submitted 2014/12/12 Platform GPL1261

At a glance

Expression microarray · mouse · 13 samples

What it is: Expression microarrayGene activity read on a chip (the older technology that RNA-seq replaced).
Organism: Mus musculus (mouse)
Samples: 13 samples
Data you can get: A processed expression table (series matrix) and the array files, from NCBI.

Summary (written by the submitters)

The first clinical trial testing the combination of targeted therapy with a BRAF inhibitor vemurafenib and immunotherapy with a CTLA-4 antibody ipilimumab was terminated early due to significant liver toxicities, possibly due to paradoxical activation of the MAPK pathway by BRAF inhibitors in tumors with wild type BRAF. MEK inhibitors can potentiate the MAPK inhibition in tumor, while potentially alleviating the unwanted paradoxical MAPK activation.

Read the full summary ↓

With a mouse model of syngeneic BRAFV600E driven melanoma (SM1), we tested whether the addition of the MEK inhibitor trametinib would enhance the immunosensitization effects of the BRAF inhibitor dabrafenib. Combination of dabrafenib and trametinib with pmel-1 adoptive cell transfer (ACT) showed complete tumor regression. Bioluminescent imaging and tumor infiltrating lymphocyte (TIL) phenotyping showed increased effector infiltration to tumors with dabrafenib, trametinib or dabrafenib plus trametinib with pmel-1 ACT combination. Intracellular IFN gamma staining of the TILs and in vivo cytotoxicity studies showed trametinib was not detrimental to the effector functions in vivo. Dabrafenib increased tumor associated macrophages and T regulatory cells (Tregs) in the tumors, which can be overcome by addition of trametinib. Microarray analysis revealed increased melanoma antigen, MHC expression, and global immune-related gene upregulation with the triple combination therapy. Given the up-regulation of PD-L1 seen with dabrafenib and/or trametinib combined with antigen specific ACT, we tested the triple combination of dabrafenib, trametinib with anti-PD1 therapy, and observed superior anti-tumor effect to SM1 tumors. Our findings support the testing of these combinations in patients with BRAFV600E mutant metastatic melanoma.

This dataset

Open GSE64102 in finder → Find more mouse microarray datasets →

Download · which file do I need?

Direct links to NCBI, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need.

All supplementary files ↗

3 · The original raw files

Whole study · RAW.tar

Everything the authors deposited as one archive (GSE64102_RAW.tar), including the raw array or instrument files. Can be large; the picker in step 2 takes just the samples you need.

Whole study · RAW.tar ↓

What the files usually look like: For arrays the series matrix is normally the normalised expression table you want; the raw array files (CEL and similar) are in the RAW.tar.

Also filed as BioProject PRJNA270119. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 25787767) ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 13 more — browse all 13 samples with per-sample file links →

Datasets on a similar topic

GSE203467 COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway [NGS2569] 12 samples shares brafv600e, braf, inhibitors
GSE264527 Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response 21 samples shares mek, immunotherapy, improved
GSE296998 Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo [RNA-seq_NaJa] 34 samples shares brafv600e, braf
GSE296999 Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo [RNA-seq_organoids] 28 samples shares brafv600e, braf
GSE306906 Fosl1 is a transcriptional effector of BRAFV600E-driven intestinal tumorigenesis 27 samples shares brafv600e, braf
GSE286241 BRAF inhibition increases TGFb2 production and stimulates metastasis in mice with endogenous BRAFV600E-induced hepatocellular carcinoma 12 samples shares brafv600e, braf
GSE301421 The kinase PLK1 promote melanoma progression in the BRAFV600E/PTEN-deficient mouse 11 samples shares brafv600e, braf
GSE212259 Whole-course Taming of Tumor-associated Macrophages from Central to Peripheral using Engineered Outer Membrane Vesicle Nanohybrids for Improved Immunotherapy [part 1: RNA-seq] 36 samples shares immunotherapy, improved

Search all mouse microarray datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.